Hepatocyte Growth Factor Suppresses Transforming Growth Factor-Beta-1 and Type III Collagen in Human Primary Renal Fibroblasts

Kaohsiung Journal of Medical Sciences

Volumn 25, Issue 11, 2009, Pages 577-587

  Mou, Shan ^a   Wang, Qin ^a   Shi, Beili ^a   Gu, Leyi ^a   Ni, Zhaohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

c Met; diabetic nephropathy; hepatocyte growth factor; interstitial fibrosis; transforming growth factor 1

Indexed keywords

COLLAGEN TYPE 3; GLUCOSE; MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; INTERVENTION STUDY; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; PATHOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELLS, CULTURED; COLLAGEN TYPE III; DIABETIC NEPHROPATHIES; DOWN-REGULATION; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70350505881     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(09)70560-1     Document Type: Article

References (27)

1. Strutz F., and Müller G.A. On the progression of chronic renal disease. Nephron 69 (1995) 371-379
2. Wolf G., and Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106 (2007) 26-31
3. Eddy A.A. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7 (1996) 2495-2508
4. Singh R., Alavi N., Singh A.K., et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48 (1999) 2066-2073
5. Yamamoto T., Nakamura T., Noble N.A., et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90 (1993) 1814-1818
6. Ziyadeh F.N., Hoffman B.B., Han C.C., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97 (2000) 8015-8020
7. Nakamura T., Nishizawa T., Hagiya M., et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342 (1989) 440-443
8. Matsumoto K., and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59 (2001) 2023-2038
9. Igawa T., Matsumoto K., Kanda S., et al. Hepatocyte growth factor may function as a renotropic factor for regeneration in rats with acute renal injury. Am J Physiol 265 (1993) F61-F69
10. Mizuno S., Kurosawa T., Matsumoto K., et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of a chronic renal disease. J Clin Invest 101 (1998) 1827-1834
11. Sorisky A., Pardasani D., Gagnon A., et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 81 (1996) 3428-3431
12. Rodmann H.P., Gerhard A.M., Aaron K., et al. Fibroblasts of rabbit kidney in culture. Am J Physiol 261 (1991) F283-F291
13. Fornoni A., Li H., Foschi A., et al. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am J Pathol 158 (2001) 275-280
14. Mizuno S., and Nakamura T. Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 55 (2004) F134-F143
15. Neaud V., Faouzi S., Guirouilh J., et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 26 (1997) 1458-1466
16. Dai C., and Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 15 (2004) 1402-1412
17. Ziyadeh F.N. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int 54 (1996) S10-S13
18. Dworkin L.D., Gong R.J., Tolbert E., et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 65 (2004) 409-419
19. Yang J., and Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159 (2001) 1465-1475
20. Schnaper H.W., Hayashida T., Hubchak S.C., et al. TGF-β signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284 (2003) F243-F252
21. Dai C., Yang J., and Liu Y. Transforming growth factor-β1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 278 (2003) 12537-12545
22. Phillips A. The role of proximal tubular cells in interstitial fibrosis: understanding TGF-beta1. Chang Gung Med J 30 (2007) 2-6
23. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287 (2004) F7-16
24. Li Y., Wen X., Spataro B.C., et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptorgamma agonists. J Am Soc Nephrol 17 (2006) 54-65
25. Taniyama Y., Morishita R., Nakagami H., et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102 (2000) 246-252
26. Taylor G.A., Jeffers M., Webb C.P., et al. Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. Oncogene 17 (1998) 1179-1183
27. Florquin S., and Rouschop K.M. Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: a role for CD44?. Kidney Int Suppl 86 (2003) S15-S20